Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe NIH banner announcing updates about a terminology transition was removed. The page continues to show a 403 error in place of the study record.SummaryDifference1%

- Check15 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe error page footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check43 days agoChange DetectedThe study record page displays a 403 Forbidden message and a Home link in place of study information.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.